Your browser doesn't support javascript.
loading
Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for action.
Anderson, Michael; Towse, Adrian; Outterson, Kevin; Mossialos, Elias.
Afiliação
  • Anderson M; Health Organisation, Policy, Economics (HOPE), Centre for Primary Care & Health Services Research, The University of Manchester, Manchester, UK; LSE Health, Department of Health Policy, The London School of Economics and Political Science, London, UK. Electronic address: michael.anderson-3@manch
  • Towse A; LSE Health, Department of Health Policy, The London School of Economics and Political Science, London, UK; Office of Health Economics, London, UK.
  • Outterson K; School of Law, Boston University, Boston, MA, USA; Combating Antibiotic- Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), Boston, MA, USA.
  • Mossialos E; LSE Health, Department of Health Policy, The London School of Economics and Political Science, London, UK; Institute of Global Health Innovation, Imperial College London, London, UK.
Lancet Microbe ; 2024 Jun 14.
Article em En | MEDLINE | ID: mdl-38885690
ABSTRACT
In June, 2023, the Council of the EU published a recommendation that the European Commission should contribute to the design and governance of an EU cross-country pull incentive to stimulate antimicrobial innovation and access. In this Personal View, we discuss six key considerations to support the implementation of the new pull incentive-ie, the size of the potential pull incentive and possible contributions of the member states, design of the incentive model, interplay of the new pull incentive with the proposed revisions of the EU pharmaceutical legislation, roles and responsibilities of both the EU and member states, balance between pull and push incentives, and global cooperation and responsibility. As the involvement of the member states with the EU pull incentive will be voluntary, member states should have confidence that the processes used to identify eligible antimicrobials, negotiate terms and conditions, and oversee access agreements are transparent, inclusive, and methodologically robust.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article